Cassava plummets 86% as simufilam phase 3 Alzheimer’s trial misses endpoints
by
Contributor since / Followers
Contributor since / Followers
1 month ago
travellinglight
- Cassava Sciences (NASDAQ:SAVA) stock has plummeted ~86% after announcing that Alzheimer’s disease candidate simufilam did not meet its co-primary endpoints in a phase 3 trial.
- Those endpoints were change in cognition and function from baseline to the end of week